Teva Pharmaceutical Industries Ltd TEVA
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 5, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
14 paragraphs in Risk Factors of the 10-K filed Feb 3, 2026 with nothing like them in the 10-K filed Feb 5, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
We also expect to continue to experience significant challenges to our global generics business. Governments worldwide continue to implement healthcare regulatory reforms aimed at reducing drug costs, including but not limited to, imposing price caps and other limits on generic medicine pricing and reimbursement policies, including as a result of inquiries into drug pricing at federal, state and international levels. Additional challenges include changes to tendering systems, a decrease in value from future launches and growth, quality and supply chain challenges, trade restrictions and tariff volatility. Failure to anticipate or adapt to these evolving changes could materially impact our operations and financial performance.
which may result in changes to the duration of and criteria for obtaining data and market exclusivity once the new legislation comes into force. See “Item 1—Business—Regulation” for more information.
Intense competition may adversely affect our ability to successfully develop and commercialize innovative medicines.
may in the future introduce new products or new variations on their existing products, our marketed products, or even those protected by patents, which have in the past and may in the future be replaced in the marketplace or we may be required to lower our prices.
For example, the following may have a significant effect on our financial results and cash flow:
We have and will continue to implement changes to optimize our business operations and reallocate resources towards growth opportunities. As part of our Pivot to Growth strategy, in May 2025, we announced the Teva Transformation programs which are expected to generate cost savings for the Company, including by examining practices and efficiencies in methods of working, reduction in headcount and optimizing external spend. In connection with these programs, we may not be able to achieve the cost savings that we expect to realize in the expected time frame due to unforeseen risks, which could impact our financial condition and ability to invest in our innovative pipeline and growth drivers.
Show the other 6
Our adoption of artificial intelligence (“AI”) technologies introduces new risks and uncertainties
Our adoption of AI technologies introduces new risks and uncertainties. These include potential inaccuracies or biases in AI outputs, cybersecurity vulnerabilities, and evolving global regulatory requirements governing AI use. Misuse or malfunction of AI systems could adversely impact our operations, reputation, or compliance. For example, use of AI technologies can lead to unintended consequences, including generating content that appears correct but is factually inaccurate, misleading or otherwise flawed, or that results in unintended biases and discriminatory outcomes, which could negatively impact individuals, harm our reputation and business, and expose us to liability. Additionally, rapid technological changes and competitive pressures may require significant ongoing investment to maintain effective and responsible AI capabilities.
In the ordinary course of our business, we are exposed to lawsuits, claims, proceedings and government investigations that could preclude or delay the commercialization of our products or disrupt our business
State has appealed that injunction, and such legislation still creates a risk of significant potential exposure for settling patent litigations and, in turn, makes it more difficult to settle in the first place, which could have a material adverse effect on our business.
We are subject to changes in governmental, investor and societal responses to climate change and sustainability-related issues, which may result in scrutiny or adverse impacts on our business.
Recent changes to investor and governmental approaches to climate change and sustainability-related issues have led to evolving and sometimes conflicting expectations and standards. From time to time, we announce certain initiatives, including goals or commitments, regarding our sustainability focus areas, which include environmental matters, sustainable procurement, health equity and access to medicines, compliance and integrity and I&D. We could be criticized for the scope of such initiatives or goals or commitments, or perceived as not
On July 4, 2025, the OBBBA was signed into law in the United States, introducing significant changes to U.S. corporate tax rules. The Act includes provisions affecting the deductibility of interest expense for U.S. federal tax purposes, the treatment of research and development costs and other depreciable property, and the taxation of foreign subsidiaries’ earnings, among other changes to U.S. corporate tax law. Under ASC 740, changes in tax rates and tax law must be recognized in the period in which the legislation is enacted. While we have evaluated the impact of this Act on our consolidated financial statements and related disclosures and it does not have a material effect on our 2025 consolidated financial statements, the ultimate impact of these provisions may differ from our estimates. Future interpretations, regulatory guidance, or changes in our business operations could result in increased tax liabilities, reduced deductions, or other adverse effects on our effective tax rate and financial condition.
As a publicly traded company, we are subject to the Securities Exchange Act of 1934 (the “Exchange Act”) and the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”). The Sarbanes-Oxley Act requires that we evaluate the effectiveness of our disclosure controls and procedures and internal control over financial reporting, and the accuracy of our financial reporting is dependent on the effectiveness of our internal controls. Our internal controls are subject to risk as a result of interpretations, assumptions and estimates in our financial reporting and accounting practices such as changes in our segment reporting. If the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, we may be required to restate our financial results, which could have a number of material adverse effects on us. In addition, any failure to maintain effective internal control over financial reporting or implement required new or improved controls could result in our inability to meet our public reporting requirements on a timely basis and properly report our financial results, a restatement of our financial statements and/or harm to our reputation, any of which could materially adversely affect our results of operations. For a discussion of our internal control over financial reporting, see “Part II, Item 9A. Controls and Procedures” of this Annual Report on Form 10-K.
Paragraphs in the 10-Q filed Nov 3, 2026 that were not in the one before
New in the latest 10-Q
119 paragraphs in the 10-Q filed Nov 3, 2026 with nothing like them in the 10-Q filed Jul 29, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Read in the 10-Q
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Read in the 10-Q
(Address of principal executive offices, zip code and telephone number, including area code)
Read in the 10-Q
As of September 30, 2026, the registrant had 1,166,826,784 ordinary shares outstanding.
Read in the 10-Q
• our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate and their effects, and effects related to the agreement we entered with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, ongoing global conflicts, including in the Middle East and war involving Iran, and the international responses including economic, trade, financial or other restrictive measures directed specifically at Israel or Israeli companies, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell or plan to sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively effectuate and consummate such sales and divestitures, including our planned divestiture of our API business;
Read in the 10-Q
Show the other 114
Financial statements and notes
* In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.
Read in the 10-Q
*** In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.
Read in the 10-Q
retrospective basis, or a full retrospective basis. The Company does not expect ASU 2025-10 to have a material impact on its consolidated financial statements.
Read in the 10-Q
In May 2025, the FASB issued ASU 2025-03 “Business Combinations and Consolidation: Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity,” which amends the guidance for determining the accounting acquirer in certain transactions. The guidance should be applied prospectively. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods, with early adoption permitted. The adoption of this guidance will affect acquisition transactions of variable interest entities that occur after the initial application date.
Read in the 10-Q
In November 2024, the FASB issued ASU 2024-03 “Income Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosures,” which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU; or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.
Read in the 10-Q
In October 2023, the FASB issued ASU 2023-06 “Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative,” which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification (“Codification”). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allow investors to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. For all entities within the scope of the affected Codification subtopics, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company does not expect ASU 2023-06 to have a material impact on its consolidated financial statements.
Read in the 10-Q
The Company has entered into asset acquisitions, alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company’s most significant agreements of this nature are summarized below.
Read in the 10-Q
The following table summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and acquired IPR&D expense as of the acquisition date:
Read in the 10-Q
(U.S. $ in millions) Cash consideration for outstanding shares, net of working capital adjustments 696 Transaction costs 8 Total consideration allocated 704 Other current assets 2 Deferred income taxes 134 Valuation allowance (134) Accrued expenses (18) Other liabilities (4) Total identifiable assets and liabilities acquired (20) Acquired IPR&D 724 Total consideration allocated 704
Read in the 10-Q
In August 2026, Teva entered into an asset sale agreement with BioXcel Therapeutics, Inc. (“BioXcel”) to serve as the stalking horse bidder in a court-supervised sale process pursuant to Section 363 of Chapter 11 of the U.S. Bankruptcy Code for the acquisition of substantially all of BioXcel’s assets, including IGALMI® (dexmedetomidine) sublingual film and the related pending supplemental New Drug Application (“sNDA”) for BXCL-501. Following the court-supervised sale process, Teva was selected as the successful bidder for the assets, and on October 21, 2026, the court approved the sale order. On October 27, 2026, Teva announced the completion of the acquisition of the neuroscience assets of BioXcel, including worldwide rights to BXCL-501 and IGALMI (dexmedetomidine) sublingual film. Under the terms of the agreement, Teva will acquire the assets for an upfront payment of $ 58 million and up to an additional $ 68 million in contingent payments. The contingent payments include time-based payments linked to the timing of the pending FDA approval of BXCL-501, including potential delays in approval, as well as payments based on the achievement of specified sales milestones. BXCL-501 is under FDA review for potential at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI is FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider.
Read in the 10-Q
In September 2026, Teva entered into a global license, development, and commercialization agreement with Samsung Bioepis (“Samsung”) for up to six biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a biosimilar candidate referencing Ilaris® (canakinumab), including an option to add up to four additional biosimilar candidates in the future. Under the terms of the agreement, Samsung will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the U.S., Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories. Each company equally shares the related development costs, subject to an aggregate cap of $ 122 million per company. In the third quarter of 2026, Teva recognized an $ 8 million upfront payment obligation as R&D expenses, which is expected to be paid in the fourth quarter of 2026. Teva and Samsung will share revenues from commercialization of these biosimilars.
Read in the 10-Q
On November 3, 2026, Teva announced that it entered into a license and commercialization agreement in the U.S. with Samsung for the commercialization of two FDA-approved immunology biosimilars, infliximab-abda, a biosimilar to Remicade® (infliximab), and ETICOVO® (etanercept-ykro), a biosimilar to Enbrel® (etanercept). Under the terms of the agreement, Samsung will be responsible for the ongoing regulatory oversight and manufacture of the biosimilars, while Teva will be responsible for commercialization in the U.S. Subject to certain conditions, Teva will pay Samsung an upfront payment of $ 50 million. Samsung may be eligible for additional milestone payments, including future launch and commercial milestone payments of up to $ 370 million. Teva and Samsung will share profit from the commercialization of these products.
Read in the 10-Q
In December 2025, Teva entered into an agreement with Polpharma Biologics International AG (“Polpharma”), which became effective in June 2026, for the commercialization of the intravenous and subcutaneous formulations of Polpharma’s proposed biosimilar to Ocrevus® (ocrelizumab). Under the terms of the agreement, Polpharma retains full responsibility for the development and manufacturing of the biosimilar candidate, and Teva will be responsible for regulatory submissions and, upon approval, commercialization of both formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey. In the third quarter of 2026, Teva paid an upfront payment and a milestone payment to Polpharma, each in the amount of $ 15 million, which were recognized as R&D expenses during the second and third quarters, respectively. Polpharma may be eligible for additional future development, regulatory and commercial milestone payments, in an aggregate amount of up to $ 92 million. Teva and Polpharma will share revenue from the commercialization of this biosimilar.
Read in the 10-Q
In April 2024, Teva announced it entered into a strategic licensing agreement with mAbxience for TEV-‘316, a biosimilar candidate currently in development for the treatment of multiple oncology indications. Under the terms of the licensing agreement, mAbxience will develop and produce the biosimilar product and Teva will lead the regulatory processes and commercialization in multiple global markets, including Europe and the U.S. In September 2024, Teva and mAbxience entered into an amendment to the licensing agreement whereby, similar to the initial licensing agreement, mAbxience will lead the development and production of TEV-‘333, an anti-PD-1 oncology biosimilar candidate and Teva will manage submissions for regulatory approvals and oversee commercialization in the designated markets.
Read in the 10-Q
In 2024, Teva paid mAbxience upfront and milestone payments of $ 20 million under the initial agreement, and $ 15 million under the amendment to the licensing agreement, which were recorded as R&D expenses. In 2025, Teva paid milestone payments in the amount of $ 29 million, which were recorded as R&D expenses. During the third quarter of 2026, Teva paid a milestone payment of $ 5 million, which was recognized as R&D expenses. mAbxience may be eligible for additional future development, regulatory and commercial milestone payments, in an aggregate amount of up to $ 286 million.
Read in the 10-Q
On March 28, 2024, Teva and Launch Therapeutics, Inc. (“Launch Therapeutics”) entered into a clinical collaboration agreement to further accelerate the clinical research program of Teva’s Dual-Action Asthma Rescue Inhaler (“DARI”) (ICS-SABA; TEV-‘248). As part of this clinical collaboration agreement, Teva also entered into a development funding agreement with funds affiliated with Abingworth LLP (“Abingworth”). Under the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, the global investment firm, has the lead role in the operational execution and management of the planned clinical trials. Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. DARI (ICS-SABA) is currently in Phase 3 for the treatment of asthma symptoms addressing both immediate symptoms and long-term inflammation.
Read in the 10-Q
On November 9, 2023, Teva entered into a funding agreement with Royalty Pharma plc. (“Royalty Pharma”) to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-’749). Under the terms of the funding agreement, Royalty Pharma will provide Teva up to $ 100 million to fund ongoing development costs for olanzapine LAI (TEV-‘749). During 2023 and 2024, Teva recorded $ 100 million as reimbursement for R&D expenses incurred in connection with this agreement, which collectively amounted to the total funding by Royalty Pharma. On December 9, 2025, Teva submitted an NDA to the FDA for olanzapine LAI (TEV-’749), based on the results from the Phase 3 trial, which was accepted by the FDA in February 2026. In May 2026, the European Medicines Agency (“EMA”) accepted Teva’s Marketing Authorization Application (“MAA”) for olanzapine LAI (TEV-’749). On October 9, 2026, Teva announced that the FDA approved WELTRUZATM (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. In the fourth quarter of 2026, Teva will recognize an expense under Other loss (income) in connection with a milestone of $ 50 million, which will be paid over four years, in addition to royalties on net sales upon commercialization that will be recorded as cost of sales in future periods.
Read in the 10-Q
In October 2021, Teva announced a license agreement with MODAG GmbH (“Modag”) providing Teva with an exclusive global license to develop, manufacture and commercialize Modag’s lead compound, emrusolmin (TEV-’286) and a related compound (TEV-’287). Teva paid an upfront payment of $ 10 million to Modag in the fourth quarter of 2021, which was recorded as R&D expenses. Emrusolmin (TEV-’286) is developed for the treatment of Multiple System Atrophy (“MSA”) and Parkinson’s disease. In the third quarter of 2024, Teva initiated a Phase 2 clinical trial for emrusolmin (TEV-’286). On November 2, 2026, Teva announced that it will discontinue the Phase 2 study evaluating emrusolmin (TEV-‘286) in adults with MSA. The decision follows a recommendation from the independent data monitoring committee (IDMC), based on a prespecified interim futility analysis, indicating a low probability of the study meeting its primary efficacy endpoint if continued. No safety concerns were identified in the interim analysis. A comprehensive analysis and evaluation of the available open-label extension study data will follow. This decision does not represent a final decision on the broader emrusolmin program. In the second quarter of 2025, Teva initiated a Phase 1 clinical trial for TEV-‘287, which is being developed for the treatment of Parkinson’s disease, and consequently paid a milestone payment of $ 10 million, which was recorded as R&D expenses. Modag may be eligible for additional future development milestone payments in an aggregate amount of up to $ 20 million, as well as future commercial milestones and royalties.
Read in the 10-Q
In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration included biosimilar candidates addressing multiple therapeutic areas, including the then proposed biosimilars to Humira® (adalimumab) and Stelara® (ustekinumab). Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the U.S. In July 2023, Alvotech and Teva amended their collaboration agreement, adding two new biosimilar candidates as well as line extensions of two current biosimilar candidates to their collaboration.
Read in the 10-Q
Teva made upfront and milestone payments in an aggregate amount of $ 154 million between 2020 and the third quarter of 2026, including a milestone payment of $ 20 million which was paid during the first quarter of 2026. Additional development and commercial milestone payments of up to approximately $ 320 million, in addition to royalty and milestone payments related to the amendment of the collaboration agreement entered into in July 2023, may be payable by Teva over the next few years. Teva and Alvotech will share revenue from the commercialization of these biosimilars.
Read in the 10-Q
The FDA approved SIMLANDI® (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira® in February 2024 and it became available in the U.S. in May 2024. On April 17, 2024, Alvotech and Teva amended their collaboration agreement to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market, with Alvotech sharing profits with Teva on the private label sales.
Read in the 10-Q
The FDA approved SELARSDI® (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara® in April 2024, and it became available in the U.S. in February 2025, and in May 2025, the FDA approved SELARSDI (ustekinumab-aekn) injection in all presentations matching the reference product, effective as of April 30, 2025.
Read in the 10-Q
In January 2025, the FDA accepted for review the Biologic License Applications (“BLA”) for Alvotech’s proposed biosimilars to Simponi® and Simponi Aria® (golimumab), and in February 2025, the FDA accepted for review the BLA for Alvotech’s proposed biosimilar to Eylea® (aflibercept). On June 4, 2026, Alvotech announced the resubmission to the FDA of BLAs for these three proposed biosimilars, following the complete response letters (CRL) received in the fourth quarter of 2025. On December 19, 2025, Alvotech and Teva announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc., concerning the launch of Alvotech’s proposed biosimilar to Eylea® (aflibercept) in the United States, granting it a license entry date in the fourth quarter of 2026. On June 8, 2026, Alvotech announced that the FDA accepted for review the BLA for its proposed biosimilar to Entyvio® (vedolizumab).
Read in the 10-Q
The second selected product candidate was olanzapine LAI (TEV-’749) for the treatment of schizophrenia. Following Teva's decision in the third quarter of 2022 to progress the development to Phase 3, Teva paid a milestone payment of $ 3 million to MedinCell, which was recognized as R&D expenses. In the first quarter of 2025, Teva paid a $ 5 million milestone payment to MedinCell, which was recognized as R&D expenses. On October 9, 2026, Teva announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults and, as a result, Teva recognized a milestone payment to MedinCell of $ 4 million. In May 2026, the EMA accepted Teva’s MAA for olanzapine LAI (TEV-‘749).
Read in the 10-Q
MedinCell may be eligible for additional development and commercial milestones of up to $ 108 million, as well as royalties on sales of olanzapine LAI (TEV-’749).
Read in the 10-Q
The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
Read in the 10-Q
The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions.
Read in the 10-Q
Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 7 years.
Read in the 10-Q
Teva’s IPR&D are assets that have not yet been approved in its major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.
Read in the 10-Q
(1) In September 2026, Teva issued senior notes in an aggregate principal amount of $ 1,200 million bearing 5.25 % annual interest and due January 2032.
Read in the 10-Q
(2) In September 2026, Teva issued senior notes in an aggregate principal amount of € 1,000 million bearing 4.25 % annual interest and due March 2033.
Read in the 10-Q
(3) In September 2026, Teva issued senior notes in an aggregate principal amount of $ 1,000 million bearing 5.50 % annual interest and due January 2034.
Read in the 10-Q
(4) In September 2026, Teva issued senior notes in an aggregate principal amount of € 500 million bearing 4.63 % annual interest and due September 2036.
Read in the 10-Q
(5) In September 2026, Teva issued senior notes in an aggregate principal amount of $ 1,000 million bearing 5.75 % annual interest and due January 2037.
Read in the 10-Q
(6) In September 2026, Teva consummated an early redemption and extinguished $ 450 million aggregate principal amount of its 4.75 % senior notes due 2027; $ 1,250 million aggregate principal amount of its 6.75 % senior notes due 2028; $ 398 million aggregate principal amount of its 7.88 % senior notes due in 2029, € 663 million aggregate principal amount of its 7.38 % senior notes due in 2029, € 1,150 million aggregate principal amount of its 4.38 % senior notes due 2030; and $ 500 million aggregate principal amount of its 8.13 % senior notes due in 2031. The extinguishment resulted in a loss of $ 224 million which was recorded under financial expenses, net.
Read in the 10-Q
(7) Debt issuance costs as of September 30, 2026, include $ 28 million in connection with the issuance of the senior notes in September 2026, partially offset by $ 14 million acceleration of issuance costs related to the early redemption.
Read in the 10-Q
(9) The Company achieved all sustainability performance targets applicable to its sustainability-linked senior notes by the respective target dates. Therefore, no one-time premium or increased interest rate payments will become payable in respect of these notes.
Read in the 10-Q
Teva maintains a committed $ 1.8 billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, as most recently amended in December 2025 (“RCF”), as part of its liquidity risk management framework and its strategy to diversify its sources of liquidity and maintain broad access to financial markets. Following the exercise of both extension options in April 2024 and December 2025, the RCF matures in April 2028. Proceeds from borrowings under the RCF may be used for general corporate purposes, and the applicable margin is linked to a sustainability performance target.
Read in the 10-Q
As a result of Teva achieving an investment grade status, the financial covenant under the RCF (maximum leverage ratio which shall not exceed 4.25 x) does not apply for so long as Teva maintains such status.
Read in the 10-Q
As of September 30, 2026, and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF.
Read in the 10-Q
In the first nine months of 2026, approximately 46 % of Teva’s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks.
Read in the 10-Q
The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, British pound, Russian ruble, Canadian dollar, Polish złoty, Japanese yen, new Israeli shekel and Indian rupee. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt.
Read in the 10-Q
The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (“net investment hedge”) and has entered into cross-currency swaps and forward-contracts in the past in order to hedge such an exposure.
Read in the 10-Q
Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company enters into derivative transactions for hedging purposes only.
Read in the 10-Q
The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans and convertible debentures that bear fixed or variable interest rates, as well as a syndicated sustainability-linked revolving credit facility and securitization programs that bear a variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (“fair value hedge”) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (“cash flow hedge”), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. As of September 30, 2026, all outstanding senior notes and sustainability-linked senior notes bear a fixed interest rate.
Read in the 10-Q
The following table summarizes the classification and fair values of derivative instruments:
Read in the 10-Q
The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships:
Read in the 10-Q
The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments:
Read in the 10-Q
Financial expenses, net Net revenues Three months ended Three months ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 414 $ 237 $ (4,395) $ (4,480) Option and forward contracts (2) 30 4 — — Option and forward contracts economic hedge (3) — — (24) (9)
Read in the 10-Q
Financial expenses, net Net revenues Nine months ended Nine months ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 854 $ 714 $ (12,519) $ (12,547) Option and forward contracts (2) 10 8 — — Option and forward contracts economic hedge (3) — — (27) 51
Read in the 10-Q
(2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.
Read in the 10-Q
(3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, British pound, Russian ruble, Canadian dollar, Polish złoty, new Israeli shekel, Indian rupee and some other currencies to protect its projected operating results in 2026 and 2027. These derivative
Read in the 10-Q
Teva maintains a trade receivables securitization program (the “EU securitization program”) to sell accounts receivable, mainly originated in Europe, to BNP Paribas Bank (“BNP”), originally established in April 2011. In August 2026, the EU securitization program was extended for an additional five-year period, through August 2031. Under the EU securitization program, Teva, on a consolidated basis through its participating subsidiaries, receives an initial cash purchase price and the right to a deferred purchase price (“DPP”), according to the purchase price for the receivables sold by it.
Read in the 10-Q
generic drug antitrust litigation, as well as a provision recorded in connection with the antitrust litigation related to QVAR. See note 10.
Read in the 10-Q
On April 30, 2018, Vanda sued Teva in the U.S. District Court for the District of Delaware asserting infringement of several Orange-Book listed patents expiring between January 2033 and May 2034 related to Vanda’s Hetlioz®. In December 2022, the Delaware District Court ruled in Teva's favor with respect to all asserted patents and Teva launched its tasimelteon product (the generic version of Hetlioz®). On May 10, 2023, the U.S. Appeals Court for the Federal Circuit affirmed the Delaware District Court's decision, in favor of Teva. Vanda filed a second lawsuit, again asserting the infringement of certain patents related to Hetlioz® which is currently pending in the U.S. District Court for the District of Delaware. Teva has counterclaims for non-infringement, invalidity, and unenforceability of Vanda’s patents. On September 25, 2026, the Delaware District Court ruled in Teva’s favor and granted summary judgment of non-infringement. Vanda will have the opportunity to appeal this decision. Should Teva ultimately be found liable for patent infringement, it could be subject to monetary damages and enjoined from further selling its tasimelteon product.
Read in the 10-Q
Teva has also been named as a defendant in product liability actions involving Paragard®, an Intrauterine device (IUD) product that Teva divested to Cooper Surgical in 2017. These actions have been consolidated by the Judicial Panel on Multidistrict Litigation in the United States District Court for the Northern District of Georgia (“Georgia MDL”). The first Georgia MDL bellwether trial concluded on February 3, 2026, with a defense verdict in Teva’s favor. In July 2026, the Georgia MDL Court entered an order scheduling the second bellwether trial to begin on April 12, 2027. On August 6, 2026, the Georgia MDL Court created a second group of bellwether cases consisting of four cases, and discovery is ongoing. There was also one related case pending in a state court in New Jersey, which was dismissed with prejudice on August 31, 2026, after the Court granted Teva's motion for summary judgement.
Read in the 10-Q
In April 2013, purported classes of direct purchasers and indirect purchasers of Niaspan® (extended-release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation was established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers’ class. The indirect purchasers’ motion for class certification was denied by the district court, and that denial was subsequently (in 2023) affirmed by the Court of Appeals for the Third Circuit. In October 2026, the district court denied cross-motions for summary judgment in the cases brought by the direct purchaser class and the direct-purchaser opt-out plaintiffs. The litigation remains ongoing. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. The California state court case has been stayed. Annual sales of Niaspan® were approximately $ 416 million at the time of the settlement and approximately $ 1.1 billion at the time Teva launched its generic version of Niaspan® in September 2013.
Read in the 10-Q
Between September 2021 and April 2022, several private plaintiffs including retailers and health insurance providers filed claims in various courts against Teva, and certain other defendants related to various medicines used to treat HIV, and these claims were all removed and/or consolidated into the U.S. District Court for the Northern District of California. As they relate to Teva, the lawsuits challenged settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva’s generic versions of Truvada® and Atripla®. In May 2023, Teva and Gilead reached a settlement agreement with the retailer plaintiffs and Teva recognized a provision for this matter based on such settlement. On June 30, 2023, the jury in the trial against the remaining plaintiffs issued a verdict in favor of Teva and Gilead, rejecting all of the remaining plaintiffs’ claims, and on February 12, 2024, the court entered a judgment consistent with the jury verdict as to all claims against Teva. The plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit, and a decision remains pending. Annual sales in the United States at the time of the settlement of Truvada® and Atripla® were approximately $ 2.4 billion, and $ 2.9 billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Truvada® in 2020 and Atripla® in 2020 were approximately $ 2.1 billion and $ 444 million, respectively.
Read in the 10-Q
On October 31, 2024, the European Commission, following a formal antitrust investigation, issued a final decision alleging that Teva had engaged in anticompetitive practices with respect to COPAXONE® in certain European member states by (i) filing and withdrawing certain divisional patents, and (ii) raising concerns about competitors’ follow-on versions of COPAXONE. The decision also includes a fine of 462.6 million euros, potentially subject to post-decision interest. In January 2025, Teva filed an appeal against the decision with the General Court of the European Union, and that appeal remains pending. In accordance with Accounting Standards Codification 450 “Accounting for Contingencies,” Teva recognized a provision in its financial statements in the third
Read in the 10-Q
quarter of 2024, based on management’s best estimate of the outcome within a range of outcomes for the final resolution of this case. Teva has provided the European Commission with surety underwritten guarantees in an amount of 462.6 million euros, together with specified post-decision interest, to cover the fine amount. Certain generic competitors in Europe have brought follow on antitrust damages claims against Teva in Germany and in the Netherlands, which have been stayed. Teva could face additional claims from generic competitors, payors, or other private plaintiffs in Europe related to this matter.
Read in the 10-Q
In November 2022, two complaints filed by plaintiffs purporting to represent retailer purchasers and a putative class of end-payor purchasers were filed in the U.S. District Court for the District of New Jersey against Teva and its marketing partner Natco Pharma Limited (“Natco”) alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by BMS) involving the drug Revlimid® (lenalidomide). The complaints also name Celgene and BMS as defendants. On January 24, 2023, the complaints were consolidated for pre-trial purposes only with an earlier-filed, already consolidated action filed against BMS and Celgene. On February 16, 2023, plaintiffs filed amended complaints adding additional plaintiffs. Additionally, on October 6, 2023, two individual payor plaintiffs brought claims similar to those described above in the U.S. District Court for the Northern District of California, which were consolidated with the pending consolidated actions and transferred to the U.S. District Court for the District of New Jersey. On June 6, 2024, the court granted in full Celgene’s motion to dismiss claims brought by certain insurer plaintiffs (Insurer Opt-Out Action), but allowed plaintiffs leave to amend most of their claims. The court had previously administratively terminated Teva’s, Natco’s, and Celgene’s motions to dismiss the retailer and end-payor complaints pending the decision on the Insurer Opt-Out Action. On August 5, 2024, plaintiffs filed amended complaints to which the defendants subsequently filed motions to dismiss. On December 16, 2024, five individual Insurer Opt-Out plaintiffs, each of whom had added Teva and Natco as defendants in the Insurer Amended Complaint filed on August 5, 2024, filed new standalone complaints naming Teva, Natco and others as defendants. On September 29, 2026, the court denied defendants’ motions to dismiss as to certain aspects of plaintiffs’ antitrust allegations concerning the 2015 patent litigation settlement. The court did not address other issues presented in defendants’ motions to dismiss, including plaintiffs’ overarching conspiracy allegations. Those issues remain pending. Annual sales of Revlimid® in the United States were approximately $ 3.5 billion at the time of the settlement.
Read in the 10-Q
In May 2023, certain end-payor plaintiffs filed putative class action complaints in the U.S. District Court for the District of Massachusetts against Teva and a number of its affiliates, alleging that Teva engaged in anticompetitive conduct to suppress generic competition to its branded QVAR asthma inhalers in violation of state and federal antitrust laws and state consumer protection laws. The court dismissed plaintiffs’ claim that Teva had engaged in “sham litigation” and certain of plaintiffs’ state antitrust and consumer protection claims, but permitted the case to proceed on the remainder of plaintiffs’ allegations. Teva recognized a provision for this matter in 2025. On August 4, 2025, the parties informed the court that they had reached a settlement in principle, which was subsequently finalized and filed, and on August 5, 2026, the Court granted final approval of the settlement.
Read in the 10-Q
In September, October, and December 2025, private plaintiffs representing (i) a putative class of end-payor purchasers, (ii) a putative class of direct purchasers; (iii) Walgreen Co., The Kroger Co., Albertsons Companies, Inc., HEB, L.P., and Supervalu, Inc., and (iv) CVS Pharmacy, Inc. (collectively with (iii), the “Retailers”), filed complaints in the United States District Court for the District of Rhode Island against Bausch Health Companies Inc., Teva, and their related entities. In December 2025, certain of the plaintiff groups identified above filed an amended complaint. The operative complaints allege violations of the antitrust laws and various state laws in connection with the companies’ September 2018 settlement of patent litigation concerning the drug Xifaxan® (rifaximin). Plaintiffs seek declaratory and injunctive relief, treble damages, attorneys’ fees, and costs of suit. On January 28, 2026 and March 25, 2026, respectively, the putative classes of end-payor purchasers and direct purchasers voluntarily dismissed their claims without prejudice. On April 16, 2026, the Retailers filed amended complaints and on September 22, 2026, Teva filed a motion to dismiss all claims against it, which motion remains pending. On July 31, 2026, Aetna, Inc., Health Care Service Corporation, and Molina Healthcare filed a complaint in the Court of Common Pleas in Allegheny County, Pennsylvania, (“State Court Action”) alleging substantially similar claims. The parties in the State Court Action filed a joint motion to stay the case on September 22, 2026, and that motion remains pending. On October 12, 2026, private plaintiffs representing a putative class of consumer purchasers filed a complaint in the United States District Court for the District of New Jersey alleging substantially similar claims. Annual sales of Xifaxan® were approximately $ 1.5 billion at the time of the settlement.
Read in the 10-Q
Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States.
Read in the 10-Q
In May 2018, Teva received a civil investigative demand from the DOJ Civil Division pursuant to its investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and/or price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. On October 10, 2024, Teva entered into a settlement agreement with the Civil Division to resolve these allegations. Under the terms of the settlement, which includes no admission of wrongdoing, Teva is required to pay $ 25 million, consisting of $ 10 million that was paid in the fourth quarter of 2024 and $ 15 million that was paid in January 2026. Teva has recognized a provision for the resolution of this matter.
Read in the 10-Q
In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. On December 15, 2016, a civil action was brought by the attorneys general of 49 states, as well as the District of Columbia and Puerto Rico, which includes claims against both Actavis and Teva. On May 10, 2019, most of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals alleging that Teva was at the center of a conspiracy in the generic pharmaceutical industry and asserting
Read in the 10-Q
that Teva and others allegedly fixed prices, rigged bids, and allocated customers and market share with respect to certain products. The second complaint was amended on November 22, 2024, to add California as a plaintiff as well as to add additional defendants. On June 10, 2020, most of the same states, with the addition of the U.S. Virgin Islands, filed a separate, third complaint in the U.S. District Court for the District of Connecticut naming, among other defendants, Actavis, in a similar complaint relating to dermatological generic products, and that complaint was later amended to, among other things, add California as a plaintiff.
Read in the 10-Q
In addition, for the complaints described above, Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022), Florida (in February 2023), Kentucky (in June 2023), South Dakota (in June 2024), and New Mexico (in June 2024). Teva paid each state an amount proportional to its share of the national population (approximately $ 1,000,000 for each 1 % share of the national population), and such states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. These settlements, in addition to the status of negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022. In the second quarter of 2025, Teva updated the provision based on recent developments in its ongoing negotiations with certain remaining U.S. state attorneys general. The States of Alabama (in March 2022) and Hawaii (in August 2023) and the territories of American Samoa (in July 2020) and Guam (in February 2023) have all voluntarily dismissed all of their claims in the litigation against Actavis and Teva USA. The dismissals by Alabama, Hawaii and Guam were with prejudice and the dismissal by American Samoa was without prejudice.
Read in the 10-Q
Beginning on March 2, 2016, and through June 2025, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs, including most recently a complaint filed by an indirect opt out plaintiff on December 2, 2025. All such complaints (other than the December 2025 complaint, as detailed below) have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (“Pennsylvania MDL”). These complaints have been brought against various manufacturer defendants, including Teva USA and Actavis, alleging that these defendants engaged in conspiracies to fix prices and/or allocate market share of generic products, and generally seeking injunctive relief and damages under federal antitrust law, as well as damages under various state laws. With limited exceptions, all fact discovery in the Pennsylvania MDL was completed in December 2025. The Pennsylvania MDL court selected two single-drug cases brought by putative classes of direct-purchaser plaintiffs (“DPPs”) and end-payor plaintiffs (“EPPs”) as bellwethers. Actavis (but not Teva) is a defendant in those cases. After selecting those two bellwether cases, the Pennsylvania MDL court certified them as class actions and proposed holding a trial in the EPP bellwether case starting in August 2025. However, on June 17, 2025, the United States Court of Appeals for the Third Circuit gave defendants permission to immediately appeal the Pennsylvania MDL court’s grant of class certification, and the Pennsylvania MDL court thereafter stayed the EPPs and DPPs bellwether cases. Briefing on the appeal was completed in December 2025, and on June 1, 2026 the Third Circuit held oral arguments on the appeal. The Pennsylvania MDL court selected five additional bellwethers: (i) Humana Inc.’s (“Humana”) indirect opt-out case, involving claims on various drugs; (ii) a case filed by a putative class of indirect reseller plaintiffs (“IRPs”) involving claims on a single drug (pravastatin); (iii) Kroger Co. (“Kroger”), a direct opt-out case, involving claims on various drugs, with trial expected in August 2027; (iv) Cigna Corp. (“Cigna”), an indirect opt-out case, involving claims on various drugs, with trial expected in January 2028; and (v) CVS Pharmacy Inc. (“CVS”), a direct opt-out case, involving claims on various drugs, where a trial date has not yet been set. As of July 2026, Teva and Actavis reached an agreement in principle to settle the IRPs’ claims, for which Teva recognized a provision in the second quarter of 2026; accordingly, and subject to finalization of that settlement, the trial previously scheduled for December 2026 is no longer expected to proceed. In October 2026, Teva and Humana reached an agreement to settle Humana’s claims, and Teva updated its provision in connection with this matter in the third quarter of 2026.
Read in the 10-Q
From 2019 to 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis. Since 2024, additional related civil complaints have been filed in state and federal courts by certain health plans, retailers, employers, counties and assignees against many of the defendants in the Pennsylvania MDL, including Teva and Actavis. These actions include, among others, complaints filed by Aetna Inc., certain counties in New York and Texas, Walmart Inc., Southwest Airlines, Inc., New York Quality Healthcare Corporation, AT&T Services, Inc., Taurus Acquisition Group, HBP I, LLC, as assignee of the antitrust claims of Great Atlantic & Pacific Tea Co., and Oak Point Partners, LLC. Most of these actions have been transferred to the Pennsylvania MDL and stayed pending outcome from the bellwether matters.
Read in the 10-Q
Plaintiffs brought a similar complaint in Canada, with allegations that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The court held a class certification hearing in October 2025 and, in February 2026, issued its decision denying class certification. In June 2026, the plaintiffs voluntarily dismissed the case with prejudice and this matter is therefore closed.
Read in the 10-Q
In March 2017, Teva received a subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting documents related to Teva’s donations to patient assistance programs. In August 2020, the U.S. Attorney’s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging causes of action under the federal False Claims Act and for unjust enrichment (the “DOJ PAP Complaint”). It was alleged that Teva’s donations to certain 501(c)(3) charities that provided financial assistance to multiple sclerosis patients violated the Anti-Kickback Statute. On October 10, 2024, Teva entered into a settlement agreement with the DOJ to resolve these claims. Under the terms of the settlement, which includes no admission of wrongdoing, Teva is required to pay $ 425 million over 6 years - $ 19 million was paid in December 2024, $ 34 million was paid in
Read in the 10-Q
January 2026, $ 49 million is due to be paid in each of December 2026 and December 2027, $ 99 million is due to be paid in December 2028, and $ 175 million is due to be paid in December 2029. The case was dismissed with prejudice on November 19, 2024. Teva has recognized a provision for the resolution of this case. Additionally, on January 8, 2021, Humana filed an action against Teva in the U.S. District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. On April 29, 2025, the court granted Teva’s motion to dismiss. On May 28, 2025, Humana re-filed the case in Kentucky circuit court, alleging the same facts alleged in the Florida district court action. On July 29, 2025, Teva filed a motion to dismiss, which the court granted in part and denied in part on January 15, 2026, leaving only claims for breach of various rebate agreements remaining. On November 17, 2022, United Healthcare filed an action against Teva in the U.S. District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint, followed by an amended complaint filed on February 29, 2024. On March 28, 2025, Teva moved for summary judgment limited to the statute of limitations defense as per the court’s order, and on July 31, 2026, the Court granted Teva’s motion for summary judgment in part, finding United Healthcare’s RICO claims are time barred, and on August 7, 2026, the Court administratively terminated Teva’s summary judgment motion with regard to the remaining state law claims.
Read in the 10-Q
On December 1, 2022, Teva received a civil subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO® and risperidone LAI. Teva cooperated with the request for documents and information and the Company has not received communication regarding this matter for several years.
Read in the 10-Q
On October 1, 2024, Teva received a civil investigative demand from the U.S. Attorney’s office in Boston, Massachusetts and the Civil Division of the Department of Justice requesting certain documents and information related to the manufacturing practices at its former manufacturing facility in Irvine, California, which Teva closed in 2022. Teva cooperated with the request for documents and information. The government requests arose from a qui tam complaint filed under seal by a former employee under the False Claims Act. The complaint was filed with the U.S. District Court for the District of Massachusetts. On May 26, 2026, the government notified the Court of its decision not to intervene. The complaint was unsealed on May 27, 2026, and Teva has not been served with a complaint.
Read in the 10-Q
Since May 2014, more than 3,500 complaints have been filed by various governmental agencies and private plaintiffs in U.S. state and federal courts with respect to opioid sales and distribution against various Teva affiliates and several other pharmaceutical companies, the vast majority of which have been resolved. The majority of the remaining cases are consolidated in the multidistrict litigation in the Northern District of Ohio (the “MDL Opioid Proceeding”). These cases assert claims under similar provisions of different state laws and generally allege that the defendants engaged in improper marketing and distribution of Teva’s branded opioids, including ACTIQ® and FENTORA®, and also assert claims related to Teva’s generic opioid products. In the first quarter of 2026, Teva and representatives for a class of third-party payers (“TPPs”) reached an agreement in principle to settle the TPPs’ opioid-related claims. No eligible TPPs opted out of the settlement, which was finalized on September 23, 2026.
Read in the 10-Q
In June 2023, Teva finalized and fully resolved its nationwide settlement agreement with the states and litigating subdivisions. Under the financial terms of the nationwide settlement agreement with the states and subdivisions, Teva will pay up to $ 4.25 billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $ 1.2 billion of Teva’s generic version of Narcan® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20 % of the wholesale acquisition cost ($ 240 million) in lieu of product.
Read in the 10-Q
Teva has settled claims brought by 100 % of the U.S. states and their litigating political subdivisions, the Native American tribes (the “Tribes”), and approximately 500 U.S. hospitals and other healthcare providers asserting opioid-related claims, including public nuisance. Teva’s estimated cash payments between 2026 and 2030 for all opioids settlements are: $ 368 million to be paid in 2026 (of which $ 354 million was paid as of September 30, 2026), $ 365 million payable in 2027; $ 416 million payable in 2028; $ 339 million payable in 2029; and $ 337 million payable in 2030. These payments are subject to change based on various factors including, but not limited to, timing of payments, most favored nations clauses associated with prior settlements, and the states’ elections to take Teva’s generic version of Narcan® (naloxone hydrochloride nasal spray). The remaining payments, subject to adjustments, will be paid beyond 2030.
Read in the 10-Q
In light of the nationwide settlement agreement between Teva and the States’ Attorneys General and their subdivisions, Teva’s indemnification obligations arising from Teva’s acquisition of the Actavis Generics business for opioid-related claims, prior
Read in the 10-Q
settlements reached with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, the Tribes, Nevada and the City of Baltimore, the agreement with the hospitals discussed above, Teva’s agreement with the TPPs, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision. The provision is a reasonable estimate of the ultimate costs for Teva’s opioids settlements, after discounting payments to their net present value. A reasonable upper end of a range of loss cannot be determined for the entirety of the remaining opioid-related cases. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva’s reputation, business, results of operations and cash flows.
Read in the 10-Q
In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include: (i) a claim brought by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, (ii) claims of municipalities, (iii) claims on behalf of various First Nations groups, and (iv) consumer class actions on behalf of persons who used opioids on behalf of themselves and putative classes. On January 22, 2025, the British Columbia Supreme Court certified the class of federal and provincial governments. Defendants appealed this decision, and in June 2026, the Court of Appeal for the British Columbia dismissed the appeal. The court in Quebec certified the class in the consumer class action in 2024 (and denied leave to appeal). In the first quarter of 2026, Teva reached an agreement in principle to settle claims by one national consumer class, brought in Ontario on behalf of persons who used opioids. Teva expects to memorialize the terms of the settlement during 2026 and to evaluate class participation before deciding whether to finalize the settlement. Other Canadian opioid actions remain in their preliminary stages.
Read in the 10-Q
On September 23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August 10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October 29, 2015 and August 18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva’s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE’s commercial success and the sustainability of Teva’s revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On November 3, 2023, the court granted plaintiff’s motion for class certification. In May 2026, the parties reached an agreement in principle to resolve this matter, and Teva recognized a provision for this matter in the second quarter of 2026, a portion of which is expected to be covered by insurance. A motion to approve a securities class action with similar allegations was also filed in September 2022 in the Central District Court in Israel, which has been stayed pending the U.S. litigation.
Read in the 10-Q
Teva or its subsidiaries are party to environmental proceedings under the federal Superfund law or other federal, provincial or state and local laws relating to alleged noncompliance, the investigation and remediation of releases of hazardous substances and natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous waste disposed of at a third party-owned site, or the party responsible for a release of hazardous substances, including per-and polyfluoroalkyl substances (PFAS), to investigate and clean-up the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have been made a party to these claims and proceedings, along with others, as an alleged generator of waste disposed of or treated at third-party waste disposal sites or as a result of an alleged release from one of Teva’s facilities or former facilities.
Read in the 10-Q
Although liability among responsible parties may be joint and several under certain circumstances, these proceedings are frequently resolved so that the allocation of clean-up and other costs among the parties reflects the relative contribution of each party to site conditions, also taking into account other relevant factors. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva’s facilities could result in the imposition of penalties (in amounts not expected to materially adversely affect Teva’s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented.
Read in the 10-Q
The following matter is disclosed pursuant to Item 103 of Regulation S-K because a governmental authority is a party and it involves monetary sanctions that could exceed $ 300,000. On July 8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva’s subsidiary in India, Teva API India Private Limited, finding non-compliance with environmental laws
Read in the 10-Q
in India and assessing a penalty of $ 1.4 million. Teva filed an appeal before the Hon’ble Supreme Court of India, disputing certain of the findings and the amount of the penalty. On August 5, 2021, the Supreme Court of India granted a stay of the judgment by the National Green Tribunal Principal Bench. On April 8, 2025, the Supreme Court of India accepted the appeal filed by Teva’s subsidiary and a hearing will be scheduled in due course. Teva does not believe that the eventual outcome of this matter will have a material effect on its business and results of operations.
Read in the 10-Q
On January 15, 2025, Teva filed a lawsuit against the Centers for Medicare and Medicaid Services (“CMS”) in the U.S. District Court for the District of Columbia, alleging that CMS’s implementation of the Drug Price Negotiation Program portion of the Inflation Reduction Act (“IRA”) of 2022 is arbitrary and contrary to the plain meaning of the statute, in violation of the Administrative Procedure Act (“APA”), and is therefore unconstitutional. On November 20, 2025, the U.S. District Court for the District of Columbia granted CMS’s motion for summary judgement. Teva has appealed this decision. On August 18, 2026, the U.S. Appeals Court for the District of Columbia Circuit issued a decision affirming that Teva’s challenge to the IRA is not barred from judicial review but finding for the government regarding CMS’ implementation of determination of Qualified Single Source Drugs. The Appeals Court also determined that Teva’s challenge to CMS’ determination of when a generic drug is marketed for purposes of implementing the IRA should continue and be returned to the district court.
Read in the 10-Q
From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from such lawsuits when they are realized or when all related contingencies have been resolved, subject to a signed or legally enforceable agreement, where applicable. No gain has been recognized regarding any matter disclosed below, unless mentioned otherwise.
Read in the 10-Q
In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly & Co.’s (“Lilly”) marketing and sale of its galcanezumab product for the treatment of migraine infringes on nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (“IPR”) petitions to the Patent Trial and Appeal Board (“PTAB”), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August 16, 2021. A jury trial regarding the three method of treatment patents resulted in a verdict in Teva’s favor on November 9, 2022. The jury’s verdict found that the three method of treatment patents were valid and infringed by Lilly and awarded Teva $ 176.5 million in damages. On September 26, 2023, the U.S. District Court for the District of Massachusetts issued a decision that reversed the jury’s verdict and damages award, finding Teva’s method of treatment patents to be invalid. Teva appealed and a hearing was held on September 5, 2025. On April 16, 2026, the U.S. Appeals Court for the Federal Circuit issued a decision in Teva’s favor, reinstating the jury’s verdict of infringement and award of damages. Lilly filed a petition seeking further review of this decision, to which Teva responded on August 3, 2026. On September 30, 2026, the Federal Circuit denied Lilly’s petition, affirming Teva’s win. Lilly will have the opportunity to seek Supreme Court review of the appeal decision. In the meantime, the case will return to the Massachusetts District Court for a final determination of the amount of damages Lilly will owe Teva.
Read in the 10-Q
In March 2024, Teva filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited, and Amarin Corporation plc (collectively “Amarin”) engaged in a decade-long scheme to lock up the supply of icosapent ethyl to prevent and delay generic competition to its branded Vascepa® drug product. Teva’s lawsuit coincides with four other lawsuits brought by generic drug manufacturers and purchasers of branded Vascepa® alleging the same or similar conduct by Amarin. Teva’s requested relief includes compensatory damages for lost sales and lost profits from generic icosapent ethyl drug sales that Teva could have made absent Amarin’s alleged interference. On May 24, 2024, Amarin filed a motion in the U.S. District Court for the District of Nevada, seeking to enforce the terms of an earlier Teva-Amarin agreement to settle patent litigation regarding Vascepa®, which Amarin asserted precluded Teva from filing the present antitrust action. On December 4, 2024, the Nevada court denied Amarin’s motion. On October 8, 2025, Amarin filed a motion with the U.S. District Court of the District of New Jersey, where the case is pending, seeking judgment on the pleadings, which was denied on February 2, 2026. Discovery is ongoing. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief.
Read in the 10-Q
In June 2024, Teva filed a lawsuit in the U.S. District Court for the Northern District of California alleging that Corcept Therapeutics, Inc. (“Corcept”) and Optime Care Inc. (“Optime”) engaged in a multifaceted, years-long scheme to stifle generic competition to Corcept’s branded Korlym® (mifepristone) drug product, which is indicated to treat endogenous Cushing’s syndrome. Teva alleges that Corcept and Optime have suppressed competition by, among other things, abusing the patent and judicial systems, entering a long-term, blanket exclusive-dealing agreement that has locked up a key pharmaceutical distribution channel, and making illicit payments to physicians as compensation for prescribing Korlym®. Teva’s requested relief includes compensatory damages for lost sales and lost profits from generic mifepristone drug sales that Teva could have made absent Corcept and Optime’s alleged interference, as well as injunctive relief to remove the unlawful barriers to generic competition created by Corcept and Optime. Teva filed an amended complaint in September 2024. Defendants filed a joint motion to dismiss in October 2024, which the court denied in substantial part on September 12, 2025. On January 29, 2026, Teva filed an amended complaint, adding a new claim for unlawful exclusive dealing against Corcept and amending certain claims that were previously dismissed. On February 5, 2026, Corcept and Optime filed briefs in support of their joint motion to dismiss, and on May 5, 2026, the court denied defendants’ motion to dismiss in substantial part. The parties filed motions for summary judgment and Daubert motions in October 2026, and those motions will be fully briefed in November 2026. As the lawsuit is still ongoing, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief.
Read in the 10-Q
Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities and its “Pivot to Growth" strategy.
Read in the 10-Q
In the nine months ended September 30, 2026, Teva recorded an expense of $ 25 million for contingent consideration, compared to an expense of $ 46 million in the nine months ended September 30, 2025.
Read in the 10-Q
Foreign currency translation adjustments Derivative financial instruments Actuarial gains (losses) and prior service (costs) credits Total
Read in the 10-Q
As of September 30, 2026 and December 31, 2025, Teva had approximately 1.3 billion ordinary shares issued, respectively. Teva ordinary shares are traded on both the Tel Aviv Stock Exchange and the New York Stock Exchange under the symbol "TEVA".
Read in the 10-Q
Prior to September 14, 2026, Teva's ordinary shares traded on the New York Stock Exchange in the form of American Depositary Shares ("ADSs"), each representing one ordinary share. On September 14, 2026, Teva's ADS program was terminated and each ADS was exchanged for one ordinary share.
Read in the 10-Q
Teva operates its business and reports its financial results in the following three segments:
Read in the 10-Q
Teva’s Chief Executive Officer (“CEO”), who is the chief operating decision maker (“CODM”), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely the United States, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance.
Read in the 10-Q
The key areas of focus by the CODM for allocation of resources are revenues from each reportable segment, as well as operating expenses (cost of sales, R&D expenses, S&M expenses, G&A expenses, and other expenses (income)). While the CODM analyzes each of these categories, the CODM focuses particularly on period-over-period fluctuations and budget-to-actual variances to determine the right allocation of resources to be attributed to each segment to ensure profitability is maximized.
Read in the 10-Q
Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva’s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment.
Read in the 10-Q
Teva’s CEO may review its strategy and organizational structure from time to time. Based on such review, in May 2023 Teva launched its new Pivot to Growth strategy. Any additional changes in strategy may lead to a reevaluation of the Company’s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 6.
Read in the 10-Q
* Segment profit includes depreciation expenses of $ 39 million in the United States, $ 33 million in Europe, and $ 18 million in International Markets.
Read in the 10-Q
* Segment profit includes depreciation expenses of $ 37 million in the United States, $ 31 million in Europe and $ 18 million in International Markets.
Read in the 10-Q
* Segment profit includes depreciation expenses of $ 111 million in the United States, $ 99 million in Europe, and $ 53 million in International Markets.
Read in the 10-Q
* Segment profit includes depreciation expenses of $ 110 million in the United States, $ 93 million in Europe, and $ 53 million in International Markets.
Read in the 10-Q
Financial items carried at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 are classified in the tables below in one of the three categories of fair value levels:
Read in the 10-Q
* Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Read in the 10-Q
On September 14, 2026, our ordinary shares began trading on the New York Stock Exchange, in lieu of the American Depositary Shares (“ADSs”), under the same ticker symbol under which the ADSs previously traded, “TEVA”. Also on September 14, 2026, our ADS program terminated, with each ADS exchanged for one ordinary share. Teva's ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, “TEVA”. Additional information is available on the investor relations section of the Company’s website, available at ir.tevapharm.com.
Read in the 10-Q
In August 2026, Teva entered into an asset sale agreement with BioXcel Therapeutics, Inc. (“BioXcel”) to serve as the stalking horse bidder in a court-supervised sale process pursuant to Section 363 of Chapter 11 of the U.S. Bankruptcy Code for the acquisition of substantially all of BioXcel’s assets, including IGALMI® (dexmedetomidine) sublingual film and the related pending supplemental New Drug Application (“sNDA”) for BXCL-501. Following the court-supervised sale process, Teva was selected as the successful bidder for the assets, and on October 21, 2026, the court approved the sale order. On October 27, 2026, we announced the completion of the acquisition of the neuroscience assets of BioXcel, including worldwide rights to BXCL-501 and IGALMI (dexmedetomidine) sublingual film. Under the terms of the agreement, Teva will acquire the assets for an upfront payment of $58 million and up to an additional $68 million in contingent payments. The contingent payments include time-based payments linked to the timing of the pending FDA approval of BXCL-501, including potential delays in approval, as well as payments based on the achievement of specified sales milestones. BXCL-501 is under FDA review for potential at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI is FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider.
Read in the 10-Q
In October 2026, we finalized an agreement with the U.S. Administration to lower the cost of select medicines for American patients covered by Medicaid. The agreement also includes a prospective Most-Favored-Nation (MFN) pricing commitment with respect to certain future innovative product launches. Additionally, Teva will maintain a dedicated reserve of certain active pharmaceutical ingredients (API) in support of public health needs and invest in U.S. pharmaceutical manufacturing.
Read in the 10-Q
• As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes, and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. In October 2026, we repaid $1,798 million of our 3.15% senior notes due 2026 at maturity. See note 7 to our consolidated financial statements.
Read in the 10-Q
On September 28, 2026, we announced that the FDA approved DEGEVMATM (denosumab-adet) as a biosimilar to Xgeva® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.
Read in the 10-Q
On October 9, 2026, we announced that the FDA approved WELTRUZATM (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the EMA accepted Teva’s MAA for olanzapine LAI (TEV-’749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.
Read in the 10-Q
Other information
During the fiscal quarter ended September 30, 2026, each of the following officers adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K). All trading plans are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 3, 2026 against Item 1A of the 10-K filed Feb 3, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:There are no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
Read in the 10-Q
1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 3, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 5, 2025
Where each one is used
- teva transformation: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- transformation programs: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- commercialize innovative: Intense competition may adversely affect our ability to successfully develop and commercialize innovative medicines.
- expected time: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- time frame: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- programs announced: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- unforeseen risks: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
- growth drivers: In order to remain competitive, we must invest significant resources to expand our pipeline for innovative medicines and biosimilars, both through our own efforts and through collaborations with, and in-licensing or acquisition of products from, third parties. We have entered into, and expect to pursue,...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
18 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.